This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
CD274 (PD-L1, B7-H1) Monoclonal Antibody (MIH5), Functional Grade, eBioscience
catalog :
16-5982-38
quantity :
5 mg
price :
US 3100.00
clonality :
monoclonal
host :
rat
conjugate :
nonconjugated
clone name :
MIH5

The same clone is also sold as:
reactivity :
mouse
application :
neutralization, flow cytometry
citations: 57
Reference
Jardim Perassi B, Irrera P, Oluwatola O, Abrahams D, Estrella V, Ordway B, et al. L-DOS47 Elevates Pancreatic Cancer Tumor pH and Enhances Response to Immunotherapy. Biomedicines. 2024;12: pubmed publisher
Noe P, Wang J, Chung K, Cheng Z, Field J, Shen X, et al. Therapeutically targeting type I interferon directly to XCR1+ dendritic cells reveals the role of cDC1s in anti-drug antibodies. Front Immunol. 2023;14:1272055 pubmed publisher
Li W, Zhao C, Li W, Gong Y, Ma K, Lu Y, et al. BRAF D594A mutation defines a unique biological and immuno-modulatory subgroup associated with functional CD8+ T cell infiltration in colorectal cancer. J Transl Med. 2023;21:737 pubmed publisher
Linnerbauer M, Beyer T, Nirschl L, Farrenkopf D, L xf6 xdf lein L, Vandrey O, et al. PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation. Nat Commun. 2023;14:5555 pubmed publisher
Chen Y, Li J, Pu L, Hu J, Fang L, Zhou F, et al. DNAJB4 suppresses breast cancer progression and promotes tumor immunity by regulating the Hippo signaling pathway. Discov Oncol. 2023;14:144 pubmed publisher
Xu S, Cai J, Cheng H, Wang W. Sustained release of therapeutic gene by injectable hydrogel for hepatocellular carcinoma. Int J Pharm X. 2023;6:100195 pubmed publisher
Blangero F, Robert M, Andraud T, Dumontet C, Vidal H, Eljaafari A. Contribution of Mesenchymal Stem Cells from Obese Adipose Tissue to PD-L1 Over-Expression and Breast Cancer Progression through Pathogenic Th17 Cell Activation. Cancers (Basel). 2023;15: pubmed publisher
Zhang G, Lan B, Zhang X, Lin M, Liu Y, Chen J, et al. AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells. J Immunother Cancer. 2023;11: pubmed publisher
Ren J, Han X, Lohner H, Hoyle R, Li J, Liang S, et al. P. gingivalis Infection Upregulates PD-L1 Expression on Dendritic Cells, Suppresses CD8+ T-cell Responses, and Aggravates Oral Cancer. Cancer Immunol Res. 2023;11:290-305 pubmed publisher
Ebelt N, Manuel E. 5-Azacytidine-Mediated Modulation of the Immune Microenvironment in Murine Acute Myeloid Leukemia. Cancers (Basel). 2022;15: pubmed publisher
Mao M, Chen Y, Yang J, Cheng Y, Xu L, Ji F, et al. Modification of PLAC8 by UFM1 affects tumorous proliferation and immune response by impacting PD-L1 levels in triple-negative breast cancer. J Immunother Cancer. 2022;10: pubmed publisher
Shen S, Li Y, Jin M, Fan D, Pan R, Lin A, et al. CD4+ CTLs Act as a Key Effector Population for Allograft Rejection of MSCs in a Donor MHC-II Dependent Manner in Injured Liver. Aging Dis. 2022;13:1919-1938 pubmed publisher
Zhang X, Halberstam A, Zhu W, Leitner B, Thakral D, Bosenberg M, et al. Isotope tracing reveals distinct substrate preference in murine melanoma subtypes with differing anti-tumor immunity. Cancer Metab. 2022;10:21 pubmed publisher
Zhao W, Wu Y, Zhao F, Xue Z, Liu W, Cao Z, et al. Scoring model based on the signature of non-m6A-related neoantigen-coding lncRNAs assists in immune microenvironment analysis and TCR-neoantigen pair selection in gliomas. J Transl Med. 2022;20:494 pubmed publisher
El Sayes N, Walsh S, Vito A, Reihani A, Ask K, Wan Y, et al. IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity. Mol Ther Oncolytics. 2022;25:16-30 pubmed publisher
Wang X, Chen Y, Lan B, Wang Y, Lin W, Jiang X, et al. Heterogeneity of tyrosine-based melanin anabolism regulates pulmonary and cerebral organotropic colonization microenvironment of melanoma cells. Theranostics. 2022;12:2063-2079 pubmed publisher
Hagemans I, Wierstra P, Steuten K, Molkenboer Kuenen J, van Dalen D, ter Beest M, et al. Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents. J Nanobiotechnology. 2022;20:64 pubmed publisher
Yang K, Choi C, Cho H, Ahn W, Kim S, Shin S, et al. Antigen-Capturing Mesoporous Silica Nanoparticles Enhance the Radiation-Induced Abscopal Effect in Murine Hepatocellular Carcinoma Hepa1-6 Models. Pharmaceutics. 2021;13: pubmed publisher
Xiang H, Chan A, Ahene A, Bellovin D, Deng R, Hsu A, et al. Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. MAbs. 2021;13:1981202 pubmed publisher
Yang Z, Xu G, Wang B, Liu Y, Zhang L, Jing T, et al. USP12 downregulation orchestrates a protumourigenic microenvironment and enhances lung tumour resistance to PD-1 blockade. Nat Commun. 2021;12:4852 pubmed publisher
Ebelt N, Zamloot V, Zuniga E, Passi K, Sobocinski L, Young C, et al. Collagenase-Expressing Salmonella Targets Major Collagens in Pancreatic Cancer Leading to Reductions in Immunosuppressive Subsets and Tumor Growth. Cancers (Basel). 2021;13: pubmed publisher
Sun Y, Jing J, Xu H, Xu L, Hu H, Tang C, et al. N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells. J Immunother Cancer. 2021;9: pubmed publisher
Eissa I, Mukoyama N, Abdelmoneim M, Naoe Y, Matsumura S, Bustos Villalobos I, et al. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8+ PD-1- tumor-infiltrating T cells in PD-L1-enriched tumor microenvironment. Int J Cancer. 2021;149:214-227 pubmed publisher
Fang W, Zhou T, Shi H, Yao M, Zhang D, Qian H, et al. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8+ T cell exclusion. J Exp Clin Cancer Res. 2021;40:4 pubmed publisher
Ferrere G, Tidjani Alou M, Liu P, Goubet A, Fidelle M, Kepp O, et al. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight. 2021;6: pubmed publisher
Yoo G, Ahn W, Kim S, Kang W, Choi C, Park H. Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study. Clin Mol Hepatol. 2021;27:144-156 pubmed publisher
Gao H, Wu Y, Shi J, Zhang X, Liu T, Hu B, et al. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy. J Immunother Cancer. 2020;8: pubmed publisher
Wu B, Chiang H, Sun X, Yuan B, Mitra P, Hu Y, et al. Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation. J Immunother Cancer. 2020;8: pubmed publisher
Liu Y, Gao Y, Hao H, Hou T. CD279 mediates the homeostasis and survival of regulatory T cells by enhancing T cell and macrophage interactions. FEBS Open Bio. 2020;10:1162-1170 pubmed publisher
Neuwelt A, Kimball A, Johnson A, Arnold B, Bullock B, Kaspar R, et al. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. J Immunother Cancer. 2020;8: pubmed publisher
Zhang J, Yamada O, Kida S, Murase S, Hattori T, Oshima Y, et al. Downregulation of PD-L1 via amide analogues of brefelamide: Alternatives to antibody-based cancer immunotherapy. Exp Ther Med. 2020;19:3150-3158 pubmed publisher
Liu Z, Wen J, Wu C, Hu C, Wang J, Bao Q, et al. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma. Aging (Albany NY). 2020;12:1213-1236 pubmed publisher
Bullock B, Kimball A, Poczobutt J, Neuwelt A, Li H, Johnson A, et al. Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLC. Life Sci Alliance. 2019;2: pubmed publisher
Shen M, Xu Z, Xu W, Jiang K, Zhang F, Ding Q, et al. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. J Exp Clin Cancer Res. 2019;38:149 pubmed publisher
Zhou Z, Chen H, Xie R, Wang H, Li S, Xu Q, et al. Epigenetically modulated FOXM1 suppresses dendritic cell maturation in pancreatic cancer and colon cancer. Mol Oncol. 2019;13:873-893 pubmed publisher
Smith H, McCaw T, Londoño A, Katre A, Meza Perez S, Yang E, et al. The antitumor effects of entinostat in ovarian cancer require adaptive immunity. Cancer. 2018;124:4657-4666 pubmed publisher
Shen M, Chen Y, Xu L, Zhu R, Xue X, Tsai Y, et al. Increased infiltration of macrophages to radioresistant lung cancer cells contributes to the development of the additional resistance of tumor cells to the cytotoxic effects of NK cells. Int J Oncol. 2018;53:317-328 pubmed publisher
Sun C, Lan P, Han Q, Huang M, Zhang Z, Xu G, et al. Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion. Nat Commun. 2018;9:1241 pubmed publisher
Zhang L, Xu L, Zhu J, Li J, Xue B, Gao J, et al. ATM‑JAK‑PD‑L1 signaling pathway inhibition decreases EMT and metastasis of androgen‑independent prostate cancer. Mol Med Rep. 2018;17:7045-7054 pubmed publisher
Zamarin D, Ricca J, Sadekova S, Oseledchyk A, Yu Y, Blumenschein W, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest. 2018;128:1413-1428 pubmed publisher
Coelho M, de Carné Trécesson S, Rana S, Zecchin D, Moore C, Molina Arcas M, et al. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA. Immunity. 2017;47:1083-1099.e6 pubmed publisher
Yang K, Blanco D, Neale G, Vogel P, Avila J, Clish C, et al. Homeostatic control of metabolic and functional fitness of Treg cells by LKB1 signalling. Nature. 2017;548:602-606 pubmed publisher
Liu Y, Marin A, Ejlerskov P, Rasmussen L, Prinz M, Issazadeh Navikas S. Neuronal IFN-beta-induced PI3K/Akt-FoxA1 signalling is essential for generation of FoxA1+Treg cells. Nat Commun. 2017;8:14709 pubmed publisher
Kalkavan H, Sharma P, Kasper S, Helfrich I, Pandyra A, Gassa A, et al. Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. Nat Commun. 2017;8:14447 pubmed publisher
Selby M, Engelhardt J, Johnston R, Lu L, Han M, Thudium K, et al. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS ONE. 2016;11:e0161779 pubmed publisher
Stifter K, Schuster C, Schlosser M, Boehm B, Schirmbeck R. Exploring the induction of preproinsulin-specific Foxp3(+) CD4(+) Treg cells that inhibit CD8(+) T cell-mediated autoimmune diabetes by DNA vaccination. Sci Rep. 2016;6:29419 pubmed publisher
Tian Y, Kuo C, Akbari O, Ou J. Maternal-Derived Hepatitis B Virus e Antigen Alters Macrophage Function in Offspring to Drive Viral Persistence after Vertical Transmission. Immunity. 2016;44:1204-14 pubmed publisher
Lagassé H, Anidi I, Craig J, Limjunyawong N, Poupore A, Mitzner W, et al. Recruited monocytes modulate malaria-induced lung injury through CD36-mediated clearance of sequestered infected erythrocytes. J Leukoc Biol. 2016;99:659-71 pubmed publisher
Bodhankar S, Chen Y, Lapato A, Vandenbark A, Murphy S, Offner H. Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke. Front Cell Neurosci. 2014;8:228 pubmed publisher
Noman M, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1?, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211:781-90 pubmed publisher
Barsoum I, Smallwood C, Siemens D, Graham C. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014;74:665-74 pubmed publisher
Yang W, Yamada M, Tamura Y, Chang K, Mao J, Zou L, et al. Farnesyltransferase inhibitor FTI-277 reduces mortality of septic mice along with improved bacterial clearance. J Pharmacol Exp Ther. 2011;339:832-41 pubmed publisher
Zheng J, Umikawa M, Zhang S, Huynh H, Silvany R, Chen B, et al. Ex vivo expanded hematopoietic stem cells overcome the MHC barrier in allogeneic transplantation. Cell Stem Cell. 2011;9:119-30 pubmed publisher
Roberts D, Franklin N, Kingeter L, Yagita H, Tutt A, Glennie M, et al. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother. 2010;33:769-79 pubmed publisher
Tomihara K, Guo M, Shin T, Sun X, Ludwig S, Brumlik M, et al. Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)Gr-1(+) cells. J Immunol. 2010;184:6151-60 pubmed publisher
Sheng H, Wang Y, Jin Y, Zhang Q, Zhang Y, Wang L, et al. A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res. 2008;18:846-57 pubmed publisher
Wang C, McDonald K, McDonough J, Newberry R. Murine isolated lymphoid follicles contain follicular B lymphocytes with a mucosal phenotype. Am J Physiol Gastrointest Liver Physiol. 2006;291:G595-604 pubmed
product information
Product Type :
Antibody
Product Name :
CD274 (PD-L1, B7-H1) Monoclonal Antibody (MIH5), Functional Grade, eBioscience
Catalog # :
16-5982-38
Quantity :
5 mg
Price :
US 3100.00
Clonality :
Monoclonal
Purity :
Affinity chromatography
Host :
Rat
Reactivity :
Mouse
Applications :
Flow Cytometry: 0.5 ug/test, Functional Assay: Assay-Dependent, Neutralization: Assay-Dependent
Species :
Mouse
Clone :
MIH5
Isotype :
IgG2a, lambda
Storage :
4 C
Description :
Programmed death receptor ligand 1 (PD-L1, also called B7-H1) is a recently described B7 family member. To date, one specific receptor has been identified that can be ligated by PD-L1. This receptor, programmed death receptor 1 (PD-1), has been shown to negatively regulate T-cell receptor (TCR) signaling. Upon ligating its receptor, PD-L1 has been reported to decrease TCR-mediated proliferation and cytokine production. PD-L1 expression was found to be abundant on many murine and human cancers and could be further up-regulated upon IFN-gamma stimulation. Thus, PD-L1 might play an important role in tumor immune evasion.
Format :
Liquid
Applications w/Dilutions :
Flow Cytometry: 0.5 ug/test, Functional Assay: Assay-Dependent, Neutralization: Assay-Dependent
Aliases :
A530045L16Rik; B7 homolog 1; B7-H; B7h1; B7-H1; Cd274; CD274 antigen; CD274 molecule; PDCD1 ligand 1; Pdcd1l1; Pdcd1lg1; Pdl1; PD-L1; pdl-1; Programmed cell death 1 ligand 1; programmed death ligand 1; RGD1566211; sCD274; soluble CD274; soluble PD L1; sPD L1
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA